Search hospitals > Maryland > Baltimore
Sinai Hospital of Baltimore
Claim this profileBaltimore, Maryland 21215
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Tumors
Conducts research for Leukemia
Conducts research for Lymphoma
388 reported clinical trials
26 medical researchers
Summary
Sinai Hospital of Baltimore is a medical facility located in Baltimore, Maryland. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Lymphoma and other specialties. Sinai Hospital of Baltimore is involved with conducting 388 clinical trials across 592 conditions. There are 26 research doctors associated with this hospital, such as Jason M. Fixler, Pallavi Kumar, MD, Qiwei W. Gai, and Ronald Delanois, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Recurrence
Global LeaderStage IV
Stage III
Stage II
Top PIs
Jason M. FixlerSinai Hospital of Baltimore7 years of reported clinical research
Expert in Tumors
Expert in Cancer
52 reported clinical trials
99 drugs studied
Pallavi Kumar, MDSinai Hospital of Baltimore1 year of reported clinical research
Studies Ovarian Cancer
Studies Recurrence
11 reported clinical trials
44 drugs studied
Qiwei W. GaiWilliam E Kahlert Regional Cancer Center/Sinai Hospital9 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
11 drugs studied
Ronald Delanois, MDSinai Hospital of Baltimore7 years of reported clinical research
Studies Osteoarthritis
Studies Knee Arthropathy
7 reported clinical trials
10 drugs studied
Clinical Trials running at Sinai Hospital of Baltimore
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Osteosarcoma
Germ Cell Tumors
Langerhans Cell Histiocytosis
Cancer
Rhabdomyosarcoma
Non-Hodgkin's Lymphoma
Brain Tumor
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Sinai Hospital of Baltimore?
Sinai Hospital of Baltimore is a medical facility located in Baltimore, Maryland. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Lymphoma and other specialties. Sinai Hospital of Baltimore is involved with conducting 388 clinical trials across 592 conditions. There are 26 research doctors associated with this hospital, such as Jason M. Fixler, Pallavi Kumar, MD, Qiwei W. Gai, and Ronald Delanois, MD.
Where is Sinai Hospital of Baltimore located?
**Directions to Sinai Hospital of Baltimore:**
- Address: 2401 W Belvedere Ave, Baltimore, MD 21215.
- From I-83 South, take exit 10 for Northern Parkway.
- Head west on Northern Parkway, turn left onto West Belvedere Avenue, and the hospital will be on your left.
Who should I call to ask about financial aid or insurance network?
**Sinai Hospital of Baltimore Contact Information**
**Financial Assistance:**
- **Phone:** 1-800-788-6995
- **Mail:** Attn: Customer Service, 5401 Old Court Rd., Randallstown, MD 21133
**Insurance:**
- **Phone:** 1-800-788-6995
- **Email:** LBHCustomerService@lifebridgehealth.org
These contacts are available for assistance with financial hardship, offering discounts for patients with an annual income up to 300% of the federal poverty level, and addressing insurance plan concerns.
What insurance does Sinai Hospital of Baltimore accept?
Sinai Hospital of Baltimore accepts numerous insurance plans, such as Advantra Freedom, Diamond Plan Medicaid, First Health, Health and Life, Indemnity, National, POS, and PPO-Health Assurance, among others. The hospital also participates in Medicare and Medical Assistance programs. For full coverage verification or if your plan is not listed, please contact Sinai Hospital or your insurance provider directly.
What awards or recognition has Sinai Hospital of Baltimore received?
Sinai Hospital of Baltimore is renowned for its contributions to medical innovation and patient care. It has earned prestigious recognitions, including a notable award that places it among the top five hospitals in Maryland and the Great Place to Work Certification for five consecutive years. The hospital also operates the Sinai Center for Thrombosis Research, focusing on translational research in thrombosis for patients undergoing interventional cardiovascular procedures.